跳至主要内容

Nanobody Preparation

 Medicilon provides camelid VHH antibody library construction services, including antigen preparation, immunization, construction of antibody library bacteria, nanobody selection, ELISA verification and other related experiments.

Nanobody Service Introduction
  • Nanobodies are superior to traditional antibodies in many ways. Based on the unique structure of VHH single-domain antibodies derived from camelid heavy chain antibodies, nanobodies combine the advantages of traditional antibodies and small molecule drugs. They almost perfectly overcome the shortcomings of long development cycles, low stability, and strict storage conditions of traditional antibodies. Nanobodies are gradually emerging as a new force in the development of therapeutic biopharmaceuticals and clinical diagnostic reagents.
    Compared to conventional antibodies, nanobodies have the following advantages:
    Small molecular weight, capable of penetrating the blood-brain barrier;High expression in prokaryotic or eukaryotic systems; strong specificity and high affinity;Strong specificity and high affinity;Weak immunogenicity in humans, etc.
M13 Phage Display Technology
  • Phage display technology is a method of expressing exogenous peptides or proteins by inserting their encoding genes into the appropriate location of the phage coat protein structural gene using genetic engineering techniques. The exogenous peptides or proteins can form fusion proteins on the coat protein of the phage during correct expression in the reading frame, and are presented on the surface of the phage along with progeny phages upon the reassembly of the phage.
    Then, using the target molecule, an appropriate panning method is used to wash away the non-specifically bound phage. The bound phages are then eluted with acid-base or competing molecules, and the neutralized phages are amplified by infecting Escherichia coli. After multiple rounds of enrichment, the proportion of phages that can specifically recognize the target molecule is gradually increased, eventually yielding peptides or proteins that recognize the target molecule.
Construction of Phage Library and Selection of Nanobodies
  • Medicilon provides unimmunized, full-age (24-36 months old) camels for antigen immunization. According to the standard immunization methods, each item is immunized with 4-6 injections. During the immunization period, ELISA titer determination services are provided to ensure that the anti-serum meets the qualified ELISA titer before blood collection and PBMC separation.
    Medicilon uses the pIII protein of M13 phage for surface display of VHH antibodies (nanobodies). Our scientists constructed a phagemid vector with double tags of HA and 6*His tag, and prepared a competent TG1 host strain with a transfection efficiency of 108. After 2-3 times of transfection and amplification, it can be used for high-quality VHH antibody display libraries with an effective library capacity greater than 108. After several rounds of nanobody library panning, at least 20 phage strains with high affinity can be obtained.
Comparison of Camel and Alpaca VHH Antibody Libraries
  • Comparison ItemCamel VHH Antibody LibraryAlpaca VHH Antibody Library
    Antigen toleranceHigh, multiple antigens can be mixed with high-dose immunizationHigher, multiple antigens can be mixed with medium immunization dose
    HCAb serum globulin ratio60%~80%20%~30%
    Neutralizing antibody titerHighHigh
    Blood collection volume200ml blood can be collected at one time80-100ml blood can be collected at one time
    Effective storage capacityHigh, immune library 108-109High, immune library 107-108
    Animal costLowerHigh
    Antigen requirement4-6mg, purity>85%4-5mg, purity>85%
Schematic diagram of nanobody preparation service process
  • Schematic diagram of nanobody preparation service process

    Image source: MA Lin-lin, et al. Construction and screening of phage display library for TIM-3 nanobody. Acta Pharmaceutica Sinica2018, 53 (3): 388-395.

Camelidae nanobody library preparation project process
  • StepContentCycleDelivery
    Step 1: Antigen preparationThe customer provides the antigen or Medicilon prepares the antigen3-4 weeksIf the customer provides the antigen, the quality standard: 1. >5mg; 2. SDS-PAGE >95%
    Step 2: Animal immunizationImmune unvaccinated camels
    5 ml unimmunized serum
    ELISA test serum titer
    10-12 weeksIf the animal dies due to antigen toxicity, a certain fee will be charged
    According to the ELISA results, client decides how to build the library
    Step 3: Antibody cDNA preparationPeripheral blood isolation of PBMC
    Extract total RNA and reverse transcribe into cDNA
    3-4 weeksProvide PBMC stored in Trizol
    Provide cDNA prepared by high-fidelity RT-PCR
    Step 4: Phage library constructionConstruction of phagemids
    Phage library construction
    VHH fragment insertion rate ≥75%
    Effective library capacity≥108CFU/mL
    Step 5: Phage library panningPhage display nanobody, panning, at least two rounds of panning
    ELISA verification, identification, screening and sequencing of positive clones (200 clones were sequenced)
    Sequencing of positive clones and analysis of sequencing results
    4-6 weeksAt least 20 sequences are guaranteed

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati